Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple test could slash use of Last-Resort antibiotics for UTIs

NCT ID NCT07675018

Diagnosis Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This trial investigates whether a rapid test for antibiotic resistance genes (integrons) can help doctors choose narrower-spectrum antibiotics for hospitalized adults with urinary tract infections (UTIs). Participants must have had a recent infection with a resistant bacterium. Those whose test is negative will receive a standard third-generation cephalosporin instead of stronger drugs like carbapenems. The goal is to see if this approach reduces the number of days patients are treated with broad-spectrum antibiotics without compromising recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Detection of integrons (diagnostic test)
What this could lead to
If successful, this test could help doctors avoid using strong, broad-spectrum antibiotics for many urinary tract infections, reducing the risk of antibiotic resistance.
What could go wrong
This is a relatively small, early-stage trial. The test may not accurately predict resistance in all cases, and the approach may not work for all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 204 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old; Hospitalized or admitted to the Emergency department; * Diagnosis of non-severe (qSOFA \< 2) urinary tract infection coupled with fever ≥ 38°C or \< 36°C * Presence of bacteria in the fresh urine sample and/or GNB on the Gram stain * Empirical parenteral antibiotic therapy required; Hospitalization required; * Former documentation of a 3GC-resistant GNB on a microbiological sample in the previous six months * Informed consent of the patient or their representative Exclusion Criteria: * Pregnant and/or breastfeeding * Neutropenia (absolute neutrophil count \< 500 / mm3) * Severe UTI with sepsis (qSOFA ≥ 2) or septic shock * Urinary derivation required (ureteral catheter/per-cutaneous nephrostomy) except for simple urinary catheterization * Known allergy to β-lactams * Patients with a former documentation with carbapenemase-producing Enterobacterales in the last 6 months * Ongoing antibiotic treatment with 3GC, piperacillin-tazobactam or carbapenem * Not affiliated to Social Security

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antibacterial agents are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial urinary tract infection urinary tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antibacterial agents Biomarkers Drug resistance, microbial Urinary tract infections (UTI's)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU Tours, Hôpital Trousseau

    Chambray-lès-Tours, 37170, France

  • CHU de Reims

    Reims, 51100, France

  • Grenoble university hospital

    La Tronche, 38700, France

  • Groupe Hospitalier Universitaire Bichat-Claude Bernard - APHP

    Paris, 75018, France

  • Hopital lariboisière

    Paris, 75010, France

  • Hôpital Saint Louis - APHP

    Paris, 75010, France

  • Limoges university hospital

    Limoges, 87042, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.